Eli Lilly plans to close three of its European facilities, including R&D sites at Hamburg in Germany and Mont-Saint-Guibert in Belgium and a manufacturing site in Basingstoke in the UK. This will result in the loss of most of the 900 jobs at the sites. “Following a strategic review of operations, these proposals are based on the increasingly challenging global pharmaceutical environment as well as Lilly’s current and future business needs. Also, consultations with employee r...